US will share up to 60 million doses of its AstraZeneca
The US will share up to 60 million doses of its AstraZeneca vaccine with other countries as they become affordable according to the White House.
After a federal safety check, the doses will be able to be shipped in the coming months.
Despite the fact that its authorities have not yet approved it for general use, the United States has a supply of the vaccine.
The government has been accused of hoarding the vaccine when other countries are in dire need.
President Joe Biden announced last month that he will share approximately four million doses of the AstraZeneca vaccine with Mexico and Canada, both of which have approved the vaccine.
The Indian crisis has increased pressure on the Biden administration to share US health-care services.
The White House said on Monday that when the Food and Drug Administration (FDA) completes its review in the coming weeks, about 10 million doses of the AstraZeneca vaccine could be released.
Another 50 million doses is said to be in different stages of development.
Jen Psaki, a White House spokeswoman, said FDA officials would conduct quality checks on doses before they were distributed.
As India fights a devastating surge in cases, the US has already declared that it will supply raw materials to vaccine manufacturers.
President Biden promised more emergency assistance "including oxygen-related equipment, vaccine materials, and therapeutics" in a "warm and optimistic" phone call with Indian Prime Minister Narendra Modi on Monday, according to a White House statement.
Pfizer BioNTech, Moderna, and Johnson & Johnson have all received FDA approval for vaccines against Covid- 19. (Janssen). According to experts, these are likely to meet all of the country's needs, and the AstraZeneca vaccine might not be needed.
According to the most recent statistics, over 53% of adults have received at least one dose of vaccine.
At the very least, it protects Joe Biden from accusations that the US has turned its back on the planet by hoarding millions of doses that were neither needed nor desired but could have saved lives.
As long as the US supply holds up, the president's domestic danger appears to be small. It reflects the administration's increasing belief that the domestic problem ahead isn't one of a lack of resources.